Neurocrine Biosciences, Inc.
NBIX
Market Cap$13.53B
Close$
$256.19
94.5% upside
Current Fair Value
94.5% upsideUndervalued by 94.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $13.53 Billion |
|---|---|
| Enterprise Value | $12.66 Billion |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $2.47 |
| Beta | 0.35 |
| Outstanding Shares | 99,507,000 |
| Avg 30 Day Volume | 953,664 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 54.17 |
|---|---|
| PEG | 82.13 |
| Price to Sales | 7.32 |
| Price to Book Ratio | 5.99 |
| Enterprise Value to Revenue | 6.71 |
| Enterprise Value to EBIT | 32.08 |
| Enterprise Value to Net Income | 50 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.08 |
Revenue Sources
No data
ESG Score
No data
About Neurocrine Biosciences, Inc.
CEO: Kevin Gorman